Mechanochemical endovenous ablation (MOCA) for the treatment of varicose veins

J. Teßarek

doi:10.12687/phleb2369-3-2017

Phlebologie, Table of Contents

Phlebologie 2017; 46(03): 150-154
DOI: 10.12687/phleb2369-3-2017

Review

Schattauer GmbH

Mechanochemical endovenous ablation (MOCA) for the treatment of varicose veins

Technique and results Article in several languages: English | deutsch

Authors

J. Teßarek

¹Gefäßchirurgie, Bonifatius Hospital, Lingen/Germany

Abstract

Summary

The endovenous therapies for varicosal veins have partially replaced surgical procedures. Beside thermal ablation based on laser or high frequency other, catheter based techniques are at hand. The non thermal mechano-chemical ablation (MOCA), that can be performed under local anesthesia, has developed as a safe and effective alternative at reasonable costs since its certification in 2011. A combination of MOCA and surgical treatment or foam sclerotherapy can be per-formed in the same setting or sequentially.

Keywords

MOCA - endovenous ablation - catheter based sclerotherapy - intumescence free procedure

Full Text

References

References
1 American College of Phlebology Practice Guidelines. Superficial Venous Disease rev102314.
2 Whiteley MS. Glue, steam and Clarivein – Best practice techniques and evidence Abstracts. Phlebology 2015; 30 2S 24-28.
3 Guex JJ, Schliephake DE, Otto J, Mako S, Allaert SA. The French polidocanol study on long term side effects, a survey covering 3357 patient years. Dermatol Surg 2010; 36 (Suppl. 02) 993-1003.
4 Baccaglini U, Spreafico G, Castoro C, Sorrentino P. Consensus Conference on Sclerotherapy or Varicose Veins of the Lower Limbs. Phlebology 1997; 12: 2-16.
5 Rabe E. (Hrsg). Grundlagen der Phlebologie. 3. erweiterte und vollständig überarbeitete Neuauflage, Köln: Viavital; 2003
6 Vin F. Principes de la Sclérothéraphie des Troncs Saphènes Internes. Phlebologie 1997; 50: 229-234.
7 Hamel-Desnos CM, Gillet JL, Desnos PR, Allaert FA. Sclerotherapy of varicous veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases. Phlebology 2009; 24: 176-182.
8 van Eekeren RR, Boersma D, Elias S. et al. Endovenous mechanochemical ablation of great saphenous vein incompetence using the ClariVein device: a safety study. J Endovasc Ther 2011; 18: 328-334.
9 Elias S, Raines JK. Mechanochemical tumescentless endovenous ablation: final results of the initial clinical trial. Phlebology 2012; 27: 67-72.
10 Kendler M, Averbeck M, Simon JC, Ziemer M. Histology of saphenous veins after treatment with the ClariVein® device – an ex-vivo experiment. JDDG 2013; 11: 348-352.
11 Lee C, Li JM, Whiteley MS. Mechanochemical Ablation (MOCA) increases endothelial damage and penetration of damage into the media layer of the vein wall compared to sclerotherapy alone – a study using histology and immunohistochemistry. Presented at: American College of Phlebology, Phoenix, November 2014.
12 van Eekeren RR, Hillebrands JL, van der Sloot K. et al. Histological observations one year after mechanochemical endovenous ablation of the great saphenous vein. J Endovasc Ther 2014; 21: 429-433.
13 Ceulen RP, Jagtman EA, Sommer A. et al. Blocking the sapheno-femoral junction during ultrasound guided foam sclerotherapy assessmant of a presumed safety-measure procedure. Eur J Vasc Endovasc Surg 2010; 40: 772-776.
14 Fachinformation Äthoxysklerol.. Stand 2011, Chemische Fabrik Keussler & Co. GmbH, Wiesbaden, Deutschland.
15 Tang TY, Kam JW, Gaunt ME. ClariVein® – early results from a large single-centre series of mechanochemical endo- venous ablation for varicose veins. Phlebology 2017; 32: 6-12.
16 Boersma D, van Eekeren RR, Werson DA. et al. Mechanochemical Endovenous Ablation of Small Saphenous Vein Insufficiency Using the ClariVein® Device: One-year Results of a Prospective Series. European Journal of Vascular and Endovascular Surgery 2013; 45: 299-304.
17 Bootun R, Lane TRA, Dharmarajah B. et al. Intra-procedural pain score in a randomized controlled trial comparing mechanochemical ablation to radiofrequency ablation: The Multicenter Venefit versus ClariVein for varicose veins trial. Phlebology 2014; 31: 61-65.
18 Vun SV, Rashid ST, Blest NC, Spark JI. Lower pain and faster treatment with mechanico-chemical endovenous ablation using ClariVein®. Phlebology 2015; 30: 688-692.
19 Ozen Y, Sarikaya S, Cekmecelioglu D. et al. Mechano-Chemical Endovenous Ablation Great Saphenous Vein Insufficiency: Two-Year Results. Damar Cer Derg [Turkish Journal of Vascular Sugery] 2015; 23: 176-179.
20 Deijen CL, Schreve MA, Bosma J, de Nie AJ, Leijdekkers VJ, van den Akker PJ, Vahl A. Clarivein mechanochemical ablation of the great and small saphenous vein: Early treatment outcomes of two hospitals. Phlebology 2016; 31: 192-197.
21 Boersma D, Kornmann VN, van Eekeren RR. et al. Treatment Modalities for Small Saphenous Vein Insufficiency: Systematic Review and Meta-analysis. J Endovasc Ther 2016; 23: 199-211.
22 Bishawi M, Bernstein R, Boter M. et al. Mechano -chemical Ablation in Patients with Chronic Venous Disease: A Prospective Multicenter Report. Phlebology 2013; 29: 397-400.
23 Witte ME, Reijnen MM, de Vreis JP, Zeebregts CJ. Mechanochemical endovenous occlusion of varicose veins using the Clarivein® device. Surg Technol Int 2015; 26: 219-225.
24 Sullivan LP, Quach G, and Chapman T. Retrograde mechanico-chemical endovenous ablation of infrageniculate great saphenous vein for persistent venous stasis ulcers. Phlebology 2014; 29: 654-657.
25 Moore HM, Lane TR, Franklin IJ. et al. Retrograde mechanochemical ablation of the small saphenous vein for the treatment of a venous ulcer. Vascular 2014; 22: 375-357.
26 Kanwar A, Hansrani M, Lees T. et al. Trends in varicose vein therapy in England: radical changes in the last decade. Ann R Coll Surg Engl 2010; 92: 341-346.
27 Marsden G, Perry M, Kelley K. Diagnosis and management of varicose veins in the legs: summary of NICE guidance. BMJ (Clinical research ed.) 2013; 347: f4279.
28 Wittens C, Davies HA, Baekgaard N. et al. Editors’s choice- management of chronic venbous disease: clinical and practical guidelines fort he European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2015; 49: 678-737.
29 Lam YL, Toonder IM, Wittens CH. Clarivein® mechano- chemical ablation an interim analysis of a randomized con- trolled trial dose-finding study. Phlebology 2016; 31: 170-176.
30 Davies HO, Popplewell M, Darvall K, Bate G, Bradbury AW. A review of randomized controlled trials comparing ultrasound-guided foam sclero-therapy with endothermal ablation for the treatment of great saphenous varicous veins. Phlebology 2016; 31: 234-240.
31 Whitley MS, Dos Santos SJ, Lee CT, Li JM. Mechanochemical ablation causes endothelial and medial damage to the vein wall resulting in deeper penetration of sclerosant compared with sclero-therapy alone in extrafascial great saphenous vein using an ex vivo model. In press, presented at the.
28 Annual Congress of the American College of Phlebology, Nov 6–9, 2014.
32 van Eekeren RR, Boersma D, Holewijn S, Vahl A, de Vries JP, Zeebregts CJ, Reijnen MM. Mechanochemical endovenous Ablation versus RADiO-frequeNcy Ablation in the treatment of primary great saphenous vein incompetence (MARADONA): study protocol for a randomized controlled trial. Trials 2014; 11: 121.
33 Boersma D, van Eekeren RR, Kelder HJ. et al. Mechanochemical endovenous ablation versus radiofrequency ablation in the treatment of primary small saphenous vein insufficiency (MESSI trial): study protocol for a randomized controlled trial. Trials 2014; 29 (Suppl. 15) 421.
34 Nakano L. Mechanochemical ablation (MOCA) for superficial venous insufficiency.
35 PROSPERO. 2017 CRD42017055127 http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42017055127.